Moderate to Severe COPD Study, Windsor

Q: Do I have to decide now?

No. Answering the questions is not a commitment - it simply lets the research team see whether this study may be appropriate and contact you to talk it through.

Q: Will it cost me anything?

No. Study visits and study assessments are provided at no cost, and reasonable travel may be reimbursed where applicable.

Q: What happens after I submit the form?

A member of the research team reviews your answers and contacts you - usually within two business days - to answer questions and review the next steps.

Q: Could I receive a placebo?

Some studies compare a treatment with a placebo. Whether this study does is explained clearly during informed consent, before you decide anything.

Q: Can I leave the study after it starts?

Yes. Participation is always voluntary. You can withdraw at any time without giving a reason and without it affecting your regular medical care.

About this study

Are you struggling with managing symptoms of Chronic Obstructive Pulmonary Disease (COPD)?

The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected.

This study is seeking participants who:

Are 35 to 80 years old
Have had moderate-to-severe COPD for at least 12 months
Have a documented history of at least 2 moderate or severe exacerbations within the last 12 months
Have been continuously taking their regular maintenance treatment(s) for COPD over at least 6 months at a stable dose for 3 months

All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied.

PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 24 weeks for the Phase 2 part and 52 weeks for the Phase 3 part. We will compare the results of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective.

Participants who will be involved in the Phase 2 part of the study for about 40 weeks. During this time, they will have 11 visits at the study clinic.

Participants who will be involved in the Phase 3 part of the study for about 68 weeks. During this time, they will have 18 visits at the study clinic.

Would you like to take part?

As a volunteer in a research study, you’ll receive study-related medical care from the study doctor and regular follow-up of your health to monitor the effectiveness of the care you’ll receive. The results of this research will be used to find out if the investigational medication being studied will be of benefit to others struggling with COPD, and whether it will be made widely available to all Canadians trying to manage this condition. Study volunteers are an important part of moving medical care forward.

Who may qualify

You may qualify if

Have had a diagnosis of chronic obstructive pulmonary disease (COPD) for at least 12 months (based on Global Initiative for Chronic Obstructive Lung Disease [GOLD] definition).
Show spirometry values (post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] less than [<] 70 percent (%) and post-bronchodilator FEV1 % predicted <70%, but greater than equal to 30%).
Have been on continuous treatment with standard of care triple therapy of LABA + LAMA + ICS for ≥ 6 months prior to Screening Visit 1 and at a stable dose for ≥3 months
Have a documented history of at least 2 moderate or severe ECOPD within the last 12 months prior to Screening.

This study may not be a fit if

Have any significant pulmonary disease other than COPD.
Have a requirement for continuous chronic treatment with oxygen at >4.0 liters / minute by nasal cannula or equivalent.
Have hypoxemia with a resting SpO2 <88% while breathing ambient air (or on the participant’s usual level of oxygen supplementation).
Have any clinically significant cardiovascular disease, acute and/or severe left heart failure, or heart failure partial ejection fraction, and/or cor pulmonale.

Every study has additional criteria the research site will review with you.

What participation may involve

Regular visits with the study team at no cost
Study assessments and health monitoring throughout
Check-ins between visits
Informed consent before anything begins — questions welcome

What participants may receive

Study-related care from a physician-led team
Study assessments at no cost
Reimbursement for reasonable travel, where applicable

Specifics vary by study and site, and are never a guarantee of benefit. Being in a study is not a substitute for regular medical care.

Participating research sites

Where this study is enrolling

WINDSOR, ONWindsor Health CentrePrincipal investigator: Dr. Syed Anees, Dr. Sabeen AnwarView site →

Learn more

About the condition

Chronic Obstructive Pulmonary Disease (COPD)

Chronic obstructive pulmonary disease, or COPD, is a long-term lung condition in which the airways are narrowed and the small air sacs deep in the lungs are damaged.…

Learn about this condition →

Other studies you can explore

All current studies →

RecruitingStudy of Initiating DepemokImab Early Therapy in Chronic Obstructive Pulmonary Disorder (COPD)WindsorCheck availability →

RecruitingStudy of Lunsekimig Compared With Placebo in Adult Participants With COPDWindsorCheck availability →

RecruitingStudy of Chronic Obstructive Pulmonary Disease (COPD) and Type 2 InflammationWindsorCheck availability →

Common questions

Do I have to decide now?

No. Answering the questions is not a commitment — it simply lets the research team see whether this study may be appropriate and contact you to talk it through.

Will it cost me anything?

No. Study visits and study assessments are provided at no cost, and reasonable travel may be reimbursed where applicable.

What happens after I submit the form?

A member of the research team reviews your answers and contacts you — usually within two business days — to answer questions and review the next steps.

Could I receive a placebo?

Some studies compare a treatment with a placebo. Whether this study does is explained clearly during informed consent, before you decide anything.

Can I leave the study after it starts?

Yes. Participation is always voluntary. You can withdraw at any time without giving a reason and without it affecting your regular medical care.

Request contact

Ask the research site to contact you

Your answers go only to the research site, help the team prepare before they call — and completing the form doesn’t obligate you to take part.

JAS Study Interest (Stream A)

See if you may qualify

A few quick questions — about a minute. Your answers help the research team prepare before they contact you.

Who may take part in this study?

Myself

Someone I care for

Age of the person who may take part

For anyone under 18, a parent or legal guardian should complete this form and would need to consent on their behalf.

Has a doctor diagnosed you (or the person who may take part) with the condition this study is about?

Yes

Not sure

Postal code (first 3 characters are enough)

Study in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

About this study

Who may qualify

What participation may involve

What participants may receive

Where this study is enrolling

Learn more

Chronic Obstructive Pulmonary Disease (COPD)

Other studies you can explore

Common questions

Ask the research site to contact you

See if you may qualify

How can we reach you?

Find a study

Health Library

The network

Contact